Related Experiment Video
Updated: Jul 26, 2026
08:35
Complete Thymectomy in Adult Rats with Non-invasive Endotracheal Intubation
Published on: December 29, 2014
Extended trans-sternal thymectomy for myasthenia gravis
1Department of Surgery II, Nagoya City University Medical School, Nagoya, Japan.
Chest Surgery Clinics of North America
|June 21, 2001
Summary
Extended thymectomy is a widely accepted and stable procedure for thymic tissue removal. Maximal thymectomy, despite higher tissue removal rates, does not yield superior results, possibly due to minimal additional tissue gain.
Area of Science:
- Thoracic Surgery
- Surgical Oncology
Background:
- Thymectomy is a surgical procedure involving the removal of the thymus gland.
- Different surgical approaches exist for thymectomy, with varying degrees of thymic tissue removal.
- The completeness of thymic tissue removal is a critical factor influencing surgical outcomes.
Purpose of the Study:
- To compare the effectiveness of different thymectomy procedures based on the completeness of thymic tissue removal.
- To investigate why maximal thymectomy does not consistently outperform extended thymectomy.
Main Methods:
- Review of existing literature and surgical outcome data.
- Classification of thymectomy procedures based on Jaretzki's grading of thymic tissue removal completeness.
- Analysis of results associated with different thymectomy techniques.
Main Results:
- Extended thymectomy (85-95% removal) is the most widely accepted procedure with prominent and stable results.
- Maximal thymectomy (98-100% removal) does not demonstrate superior outcomes compared to extended thymectomy.
- The results of thymectomy do not always correlate directly with the percentage of thymic tissue removed.
Conclusions:
- Extended thymectomy offers a reliable and effective approach for thymectomy.
- Further investigation is needed to understand the factors contributing to the outcomes of maximal thymectomy, potentially related to minimal incremental tissue removal.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...